Foamix Announces Appointment of Anthony Bruno to Board of Directors
“We are delighted to welcome Tony to our Board of Directors,” said Dr.
“This is a very exciting time for Foamix, with the recent successful Phase 3 clinical trial results for FMX101 in acne and FM103 in rosacea,” said
Mr. Bruno was a strategic advisor to Foamix from 2014 until 2018. He was employed at Warner Chilcott from 2000 to 2011, most recently as Executive Vice President with responsibility for all business development activities including product acquisitions and divestitures as well as licensing agreements. Prior to this, he served as General Counsel for Warner Chilcott where he was responsible for all legal activities. During his time at Warner Chilcott, he led the efforts to in-license the company’s dermatology portfolio from LEO Pharma, as well as the subsequent sale back of the portfolio to LEO. Additionally, Mr. Bruno was responsible for the acquisition of Pfizer’s female healthcare business and the acquisition of Proctor and Gamble’s pharmaceutical business. Mr. Bruno was also a member of the executive team that worked with a consortium of four private equity funds to take Warner Chilcott private and subsequently public on NASDAQ 18 months later.
From 1984 to 2000, Mr. Bruno held several positions of increasing responsibility within Warner Lambert’s legal division, culminating as General Counsel to the company’s pharmaceutical business. During his 16 years at Warner Lambert, he worked on the Lipitor co-promotion agreement with Pfizer, the announced merger with American Home Products, and the acquisition of Warner Lambert by Pfizer. Prior to working in the pharmaceutical industry, Mr. Bruno began his legal career as an associate with
Foamix is a specialty pharmaceutical company focused on the development and commercialization of proprietary, innovative and differentiated topical drugs for dermatological therapy. Our leading clinical stage product candidates are FMX101, our novel minocycline foam for the treatment of moderate-to-severe acne and FMX103, our novel minocycline foam for the treatment of rosacea. We continue to pursue research & development of our proprietary, innovative foam technologies for the treatment of various skin conditions. We currently have development and license agreements relating to our technology with various pharmaceutical companies including LEO Pharma A/S and others.
Foamix uses its website (www.Foamix.com) as a channel to distribute information about Foamix and its product candidates from time to time. Foamix may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor Foamix’s website in addition to following its press releases, filings with the
|Contact:||U.S. Investor Relations|
|Ilan Hadar, CFO & Country Manager||Michael Rice|
|Foamix Pharmaceuticals Ltd.||LifeSci Advisors, LLC|
Source: Foamix, Ltd.